Evidence map›Paper›PMID 24672477›Full record

ArticleFrontiers in aging neuroscience2014

Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications.

Jun Wang, Weina Bi, Alice Cheng, Daniel Freire, Prashant Vempati, Wei Zhao, Bing Gong, Elsa M Janle, Tzu-Ying Chen, Mario G Ferruzzi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in aging neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Benefits of dietary polyphenols in Alzheimer's disease.Frontiers in aging neuroscience · 2022
    Review
  14. Evaluation ofFrontiers in pharmacology · 2022
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jun WangDepartment of Neurology, Icahn School of Medicine at Mount Sinai New York, NY, USA ; Geriatric Research, Education and Clinical Center, James J. Peters Veterans Affairs Medical Center Bronx, NY, USA.
Weina BiDepartment of Neurology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Alice ChengDepartment of Neurology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Daniel FreireDepartment of Neurology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Prashant VempatiDepartment of Neurology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Wei ZhaoDepartment of Neurology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Bing GongDepartment of Neurology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Elsa M JanleDepartments of Food Science and Foods and Nutrition, Purdue University West Lafayette, IN, USA.
Tzu-Ying ChenDepartments of Food Science and Foods and Nutrition, Purdue University West Lafayette, IN, USA.
Mario G FerruzziDepartments of Food Science and Foods and Nutrition, Purdue University West Lafayette, IN, USA.
James SchmeidlerDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Lap HoDepartment of Neurology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Giulio M PasinettiDepartment of Neurology, Icahn School of Medicine at Mount Sinai New York, NY, USA ; Geriatric Research, Education and Clinical Center, James J. Peters Veterans Affairs Medical Center Bronx, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease of aging and currently has no cure. Its onset and progression are influenced by multiple factors. There is growing consensus that successful treatment will rely on simultaneously targeting multiple pathological features of AD. Polyphenol compounds have many proven health benefits. In this study, we tested the hypothesis that combining three polyphenolic preparations (grape seed extract, resveratrol, and Concord grape juice extract), with different polyphenolic compositions and partially redundant bioactivities, may simultaneously and synergistically mitigate amyloid-β (Aβ) mediated neuropathology and cognitive impairments in a mouse model of AD. We found that administration of the polyphenols in combination did not alter the profile of bioactive polyphenol metabolites in the brain. We also found that combination treatment resulted in better protection against cognitive impairments compared to individual treatments, in J20 AD mice. Electrophysiological examination showed that acute treatment with select brain penetrating polyphenol metabolites, derived from these polyphenols, improved oligomeric Aβ (oAβ)-induced long term potentiation (LTP) deficits in hippocampal slices. Moreover, we found greatly reduced total amyloid content in the brain following combination treatment. Our studies provided experimental evidence that application of polyphenols targeting multiple disease-mechanisms may yield a greater likelihood of therapeutic efficacy.

Indexed as

Alzheimer's disease (AD)grape juicegrape seed extractJ20 micepolyphenolsresveratrol

Identifiers

PMID24672477
PMCPMC3954102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.